American Century Companies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10,773
Closed -$1.42M 2988
2025
Q1
$1.42M Sell
10,773
-303,589
-97% -$37.8M ﹤0.01% 2114
2024
Q4
$26.3M Buy
314,362
+63,423
+25% +$5.21M 0.02% 922
2024
Q3
$18.4M Sell
250,939
-18,044
-7% -$1.36M 0.01% 1059
2024
Q2
$18.4M Sell
268,983
-273,930
-50% -$19M 0.01% 990
2024
Q1
$37.6M Buy
542,913
+62,663
+13% +$4.31M 0.02% 670
2023
Q4
$34.4M Buy
480,250
+38,840
+9% +$2.23M 0.02% 652
2023
Q3
$23M Buy
441,410
+21,604
+5% +$1.26M 0.02% 754
2023
Q2
$26.6M Buy
419,806
+76,429
+22% +$4.76M 0.02% 661
2023
Q1
$18.6M Buy
343,377
+3,715
+1% +$180K 0.01% 784
2022
Q4
$18M Buy
339,662
+21,867
+7% +$1.1M 0.01% 764
2022
Q3
$14.8M Sell
317,795
-1,504
-0.5% -$78.6K 0.01% 753
2022
Q2
$18.2M Buy
319,299
+128,636
+67% +$7.29M 0.01% 705
2022
Q1
$11.7M Buy
190,663
+181,156
+1,906% +$9.41M 0.01% 858
2021
Q4
$498K Buy
9,507
+886
+10% +$37.2K ﹤0.01% 1931
2021
Q3
$321K Buy
8,621
+703
+9% +$24.4K ﹤0.01% 2059
2021
Q2
$323K Buy
+7,918
New +$293K ﹤0.01% 2032
2018
Q1
Sell
-65,330
Closed -$946K 1351
2017
Q4
$946K Hold
65,330
﹤0.01% 1109
2017
Q3
$1.03M Buy
+65,330
New +$959K ﹤0.01% 1139
2016
Q3
Sell
-48,896
Closed -$1.9M 1424
2016
Q2
$1.9M Buy
+48,896
New +$1.76M ﹤0.01% 1035

Other funds holding ITCI

American Century Companies's ITCI Position: Q2 2025 in Review

American Century Companies sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 10,773 shares — an estimated $1.42M sold.

American Century Companies first reported a position in ITCI in Q2 2016 and held it in 19 quarters. The position peaked at $37.6M in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • American Century Companies reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • American Century Companies sold 10,773 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.42M.
  • American Century Companies first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 19 quarters.
  • American Century Companies's Intra-Cellular Therapies Inc. position peaked at $37.6M in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on American Century Companies's 13F filing for Q2 2025, filed 12 Aug 2025.